Key facts
- Human Longevity’s last known valuation is $250.0M.
- It has raised $1.1B across 3 recorded rounds; the latest was Early Stage VC ($32.0M) in Mar 2023.
- Notable investors include CONNECT(San Diego), Amino Capital, OS Fund, NKM Capital, Panacea Venture — 36 tracked in total.
- Human Longevity has filed 4 Form Ds with the SEC since 2019, most recently Aug 2024 ($32.0M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 36 names
- ·Watchlist + deal alerts for Human Longevity
Funding rounds
3 roundsAbout Human Longevity
Developer of a biotechnology platform designed to combine genomic and phenotypic information to accelerate the understanding of human health. The company's platform addresses the age-related decline in endogenous stem cell function and concentrates on cancer, diabetes, obesity, heart and liver diseases, and dementia by combining deoxyribonucleic acid sequencing and expert analysis with machine learning, enabling people to shape their health and shift the practice of medicine from reactive to proactive technologies.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 81
- Website
- humanlongevity.com/
- Ownership
- Privately Held (backing)
Human Longevity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Human Longevity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Human Longevity in its N-PORT filings yet. We sweep new filings monthly.